LIVN at a glance
LivaNova PLC (LIVN, SEC CIK 1639691) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), LivaNova PLC (LIVN) reported revenue of $1.4 billion (up 10.7% from FY2024) and a net loss of $242.5 million. Diluted EPS was -$4.45.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding LivaNova PLC (LIVN) shares worth $2.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bianchi Francesco on September 10, 2026 of 3,500 shares at $78.01 per share.
- In the last 90 days, LIVN insiders reported 0 open-market purchases ($0) and 4 open-market sales ($800K) on Form 4, a net sale of $800K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.4B
- +10.7% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$800K
- 13F holders
- 31 funds
- $2.2B · −1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Revenue and YoY change not disclosed explicitly in provided text
- No profitability or margin % figures available in text
- Cash flow, buybacks, dividends, capex details not included
- Risks from FX volatility, inflation, geopolitical instability, supply chain challenges highlighted as key emerging risks
Business Overview
- Core business model: Medical technology company with Cardiopulmonary and Neuromodulation segments driving revenue
- New product emphasis: aura6000 System for treating Obstructive Sleep Apnea, increasing Neuromodulation R&D expense by $11.2M
- Strategic shift: Reduced litigation provision for 3T Heater-Cooler device by $15.3M, improving Cardiopulmonary segment income
- Quantitative metric: Net revenue up 10.7% to $1.39B; Cardiopulmonary revenue up 14.9%, Neuromodulation up 7.0% YoY
- Noteworthy fact: $366M SNIA environmental liability expense recorded due to 2025 Italian Supreme Court ruling on joint liability
Risk Factors
- Regulatory risk from 3T Heater-Cooler device litigation provision reducing cash outflows by $71.3M in 2025
- Geopolitical risk from exposure to hospital and healthcare sectors across multiple countries affecting trade receivables concentration
- Operational risk from increased investing activities $33.9M in plant, property, and software for manufacturing capacity expansion
- Competitive risk from sale of Ceribell, Inc. investment for $6.5M indicating strategic shift or response to market
- Financial risk from debt reduction $280.9M in 2025 lowered debt from $627.6M to $376.7M, decreasing leverage ratio from 47.5% to 31.4% equity
AI summary of the LIVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $390.6M, up 10.8% YoY from $352.5M
- Gross margin 70.1% vs 67.8% YoY, with cost of sales 29.9% vs 32.2%
- Best segment Neuromodulation revenue $166.9M, up 10.1%; segment income $60.9M, up 8.8%
- Worst segment Cardiopulmonary income $28.2M, down 10.4% despite revenue up 11.2% to $221.6M
- Cash $516.6M vs $635.6M year-end; operating cash flow $81.8M, down from $86.9M, after $95.9M debt repayment
- Near-term headwinds: FX volatility, inflation, tariffs, supply-chain constraints, and potential trade restrictions
Risk Factors
- Iran sanctions-compliance exposure from sales through distributors and a nongovernmental organization
- Limited customer visibility creates potential dealings with Iranian government-owned hospitals or sub-distributors
- Iran revenue $1.8 million and net profit $0.9 million in the quarter ended June 30, 2026
- Evolving U.S., UK, and EU sanctions laws increase compliance uncertainty as LivaNova continues Iran operations
AI summary of the LIVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Quarterly results cover the period ended June 30, 2026
- Earnings press release furnished as Exhibit 99.1, containing the substantive financial details
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 10 AGM resolutions passed, preserving board continuity and approved governance measures
- All 11 directors re-elected for terms through the 2027 AGM, with votes against ranging from 96,890 to 517,219
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results cover the quarter ended March 31, 2026
- Conference call and webcast scheduled May 6, 2026 at 1 p.m. London time
AI summaries of LIVN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LIVN
Don't miss the next LIVN filing
- Alerts as it files. A push when LIVN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LIVN, by share count.
- Ask anything. An AI agent that reads every LIVN filing and answers with sources.
LIVN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Liddy Anne M. | A | Sep 15, 2026 | 6,291 | - |
| Bianchi Francesco | Sell | Sep 10, 2026 | 3,500 | $78.01 |
| Story Brooke | Sell | Sep 4, 2026 | 2,300 | $81.42 |
| Bianchi Francesco | Sell | Aug 31, 2026 | 1,650 | $79.72 |
| Tezel Ahmet | M | Aug 11, 2026 | 12,692 | - |
| Tezel Ahmet | M | Aug 11, 2026 | 12,692 | $52.68 |
| Tezel Ahmet | F | Aug 11, 2026 | 1,428 | $77.86 |
| Tezel Ahmet | D | Aug 11, 2026 | 8,589 | $77.86 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.3B | $1.4B |
| Gross Profit | - | $870.9M | $939.9M |
| Operating Income | - | $129.1M | $199.4M |
| Net Income | - | $63.2M | -$242.5M |
| Gross Margin | - | 69.5% | 67.7% |
| Op. Margin | - | 10.3% | 14.4% |
| Net Margin | - | 5.0% | -17.5% |
| Balance Sheet | |||
| Total Assets | $2.4B | $2.5B | $2.6B |
| Equity | $1.3B | $1.3B | $1.2B |
| ROE | - | 4.8% | -20.2% |
| Per Share | |||
| EPS | - | $1.16 | $-4.45 |
| Cash Flow | |||
| Operating CF | - | $183.0M | $254.3M |
| CapEx | - | $47.1M | $81.0M |
Source: XBRL data in LivaNova PLC (LIVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LIVN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $2.17B |
| Q1 2026 | 32 | $1.73B |
| Q4 2025 | 28 | $1.53B |
| Q3 2025 | 29 | $1.30B |
| Q2 2025 | 29 | $1.14B |
| Q1 2025 | 26 | $605.2M |
| Q4 2024 | 22 | $642.9M |
| Q3 2024 | 19 | $582.5M |
- Invesco Ltd+613.1K (+38%)
- FMR LLC (Fidelity)+480.4K (+18%)
- BlackRock+426.4K (+6%)
- Citigroup+129.3K (+390%)
- State Street Corp+93.2K (+4%)
- Millennium Management−1.94M (-79%)
- Morgan Stanley−418.3K (-70%)
- AQR Capital Management−138.2K (-6%)
- Ameriprise Financial−115.3K (-28%)
- Goldman Sachs Group−103.2K (-13%)
- Truist Financial+2.5K
- D.E. Shaw & Co−26.2K
- Citadel Advisors LLC−22.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 216 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LIVN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 27, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CBLL · Ceribell, Inc.Electromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
LIVN SEC filings: frequently asked questions
Are LIVN insiders buying or selling?
In the last 90 days, LivaNova PLC (LIVN) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $799,783 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LIVN stock?
As of June 30, 2026, the largest LivaNova PLC (LIVN) holders among the 13F filers tracked by SignalX were BlackRock ($622.1 million), FMR LLC (Fidelity) ($258.8 million), AQR Capital Management ($191.0 million), Invesco Ltd ($184.0 million), State Street Corp ($178.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LIVN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), LivaNova PLC (LIVN) reported revenue of $1.4 billion (up 10.7% from FY2024) and a net loss of $242.5 million. Diluted EPS was -$4.45. The figures come from the XBRL data in the 10-K.
What are the main risks in LIVN's latest 10-K?
In the 10-K filed February 25, 2026, LivaNova PLC (LIVN) flagged: Regulatory risk from 3T Heater-Cooler device litigation provision reducing cash outflows by $71.3M in 2025. Geopolitical risk from exposure to hospital and healthcare sectors across multiple countries affecting trade receivables concentration. (AI summary of the Risk Factors section.)
What did LIVN report in its latest 8-K?
LivaNova PLC (LIVN) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Quarterly results cover the period ended June 30, 2026.
What are the latest LIVN SEC filings?
LivaNova PLC (LIVN) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 16, 2026.
What is LIVN's SEC CIK number?
LivaNova PLC (LIVN)'s SEC Central Index Key (CIK) is 1639691. EDGAR lists every LIVN filing under that number.
Ask anything about LIVN
The research agent reads LIVN's filings, financials, insider trades and 13F holders, then answers with sources.